Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies (Q34648414)

3 August 2017

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies (English)

1 reference

3 August 2017

0 references

0 references

0 references

11

Claudia Trenkwalder

0 references

Michael G Schlossmacher

object named as

Michael G Schlossmacher

6

0 references

Jens Wiltfang

object named as

Jens Wiltfang

8

0 references

Brit Mollenhauer

1

object named as

Brit Mollenhauer

1 reference

3 August 2017

2

Petra Steinacker

1 reference

3 August 2017

4

Mirko Bibl

1 reference

3 August 2017

5

Peter Brechlin

1 reference

3 August 2017

9

Hans A Kretzschmar

1 reference

3 August 2017

Erik Bahn

3

1 reference

3 August 2017

Joseph J Locascio

7

1 reference

3 August 2017

Sigrid Poser

10

1 reference

3 August 2017

Markus Otto

12

1 reference

3 August 2017

language of work or name

1 reference

6 July 2007

1 reference

Neurodegenerative Diseases

3 August 2017

1 reference

3 August 2017

4

1 reference

3 August 2017

5

1 reference

3 August 2017

366-375

1 reference

Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

3 August 2017

1 reference

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease

21 January 2018

1 reference

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

21 January 2018

1 reference

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man

21 January 2018

1 reference

Detection of brain injury by fatty acid-binding proteins

21 January 2018

1 reference

Fatty acid-binding proteins of nervous tissue

21 January 2018

1 reference

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice

21 January 2018

1 reference

Yeast genetics targets lipids in Parkinson's disease

21 January 2018

1 reference

Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies

21 January 2018

1 reference

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease

21 January 2018

1 reference

alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins

21 January 2018

1 reference

Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies.

21 January 2018

1 reference

Dysautonomia in Parkinson's disease: neurocardiological abnormalities

21 January 2018

1 reference

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

Fatty acid-binding proteins as plasma markers of tissue injury

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

21 January 2018

1 reference

Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast

21 January 2018

1 reference

Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study.

21 January 2018

1 reference

Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility

21 January 2018

1 reference

Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.

21 January 2018

1 reference

Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease

21 January 2018

1 reference

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000105157

1 reference

3 August 2017

1 reference